Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates

Blood

Volumn 94, Issue 9, 1999, Pages 3121-3128

  Rots, Marianne G ^a   Pieters, Rob ^b   Peters, Godefridus J ^b   Van Zantwijk, Christina H ^b   Mauritz, Rob ^b   Noordhuis, Paul ^b   Willey, James C ^b   Hählen, Karel ^b   Creutzig, Ursula ^b   Janka Schaub, Gritta ^b   Kaspers, Gertjan J L ^b   Veerman, Anjo J P ^b   Jansen, Gerrit ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; FOLIC ACID ANTAGONIST; METHOTREXATE; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; TRIMETREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; DRUG EXPOSURE; DRUG POTENCY; DRUG SENSITIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRELEUKEMIA; PRIORITY JOURNAL;

EID: 0033230901     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.9.3121     Document Type: Article

References (51)

1. Pui CH, Evans WE: Acute lymphoblastic leukemia, N Engl J Med 339:605, 1998
2. Evans WE, Relling MV, Rodman JH, Cram WR, Boyett JM, Pui C-H: Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499, 1998
3. Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT, Pui C-H, Evans WE: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo, a rationale for high-dose methotrexate. J Clin Invest 97:73, 1996
4. Whitehead VM, Rosenblatt DS, Vuhich M-J, Shuster JJ, Witte A, Beaulieu D: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: A pilot prognostic factor analysis. Blood 76:44, 1990
5. Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK: Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 81:602, 1993
6. Henze G, Fengler R, Hartmann R, Kornhuber B, Janka-Schaub G, Niethammer D, Riehm H: Six-year experience with a comprehensive approach to the treatment of recurrent childhood acute lymphoblastic leukemia (ALL-REZ BFM 85). A relapse study of the BFM group. Blood 78:1166, 1991
7. Gorlick R, Göker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, Flintoff WF, Bertino JR: Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89:1013, 1997
8. Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S, Williamson M, Amylon M, Pullen J, Camitta B, Ravindranath Y: Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood 90:578, 1997
9. Göker E, Waltham M, Kheradpour A, Trippett T, Mazumdar M, Elisseyeff Y, Schnieders B, Steinherz P, Tan C, Berman E, Bertino JR: Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 86:677, 1995
10. Spencer HT, Sorrentino BP, Pui CH, Chunduru SK, Sleep SE, Blakley RL: Mutations in the gene for human dihydrofolate reductase: An unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia 10:439, 1996
11. Gorlick R, Göker E, Trippett T, Waltham M, Banerjee D, Bertino JR: Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 335:1041, 1996
12. Rots MG, Pieters R, Kaspers GJL, Van Zantwijk CH, Noordhuis P, Mauritz R, Veerman AJP, Jansen G, Peters GJ: Differential methotrexate resistance in childhood T-versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay. Blood 93:1067, 1999
13. Göker E, Lin JT, Trippett T, Elisseyeff Y, Tong WP, Niedzwiecki D, Tan C, Steinherz P, Schweitzer BI, Bertino JR: Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 7:1000, 1993
14. Rots MG, Pieters R, Peters GJ, Noordhuis P, Van Zantwijk CH, Hählen K, Creutzig U, Kaspers GJL, Veerman AJP, Jansen G: The role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 93:1677, 1999
15. Synold TW, Relling MV, Boyett JM, Rivera GK, Sandlund JT, Mahmoud H, Crist WM, Pui CH, Evans WE: Blast cell methotrexatepolyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest 94:1996, 1994
16. Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui CH, Relling MV, Evans WE: Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 52:155, 1997
17. Barredo JC, Synold TW, Laver J, Relling MV, Pui CH, Priest DG, Evans WE: Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 84:564, 1994
18. Goldman DI, Matherly LH: The cellular pharmacology of methotrexate. Pharmacol Ther 28:77, 1985
19. Bender RA: Anti-folate resistance in leukemia: Treatment with "high-dose" methotrexate and citrovorum factor. Cancer Treat Rev 2:215, 1975
20. Pui C-H: Childhood Leukemias. N Engl J Med 332:1618, 1995
21. Kaspers GJL, Kardos G, Pieters R, Van Zantwijk CH, Klumper E, Hählen K, De Waal FC, Van Wering ER, Veerman AJP: Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: A preliminary report. Leukemia 8:1224, 1994
22. Estlin EJ, Ablett S, Newell DR, Lewis IJ, Lashford L, Pearson AD: Phase I trials in paediatric oncology - the European perspective. The New Agents Group of the United Kingdom Childrens Cancer Study Group. Invest New Drugs 14:23, 1996
23. Weitman S, Carlson L, Pratt CB: New drug development for pediatric oncology. Invest New Drugs 14:1, 1996
24. Lin JT, Tong WP, Trippett TM, Niedzwiecki D, Tao Y, Tan C, Steinherz P, Schweitzer BI, Bertino JR: Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res 15:1191, 1991
25. Yamauchi H, Iwata N, Omine M, Maekawa T: In vitro methotrexate polyglutamate formation is elevated in acute lymphoid leukemia cells compared with acute myeloid leukemia and normal bone marrow cells. Acta Haematol Jpn 51:766, 1988
26. Longo GS, Gorlick R, Tong WP, Ercikan E, Bertino JR: Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 90:1241, 1997
27. Dedhar S, Hartley D, Fitz-Gibbons D, Phillips G, Goldie JH: Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 3:1545, 1985
28. Mauritz R, Bekkenk M, Rots MG, Pieters R, Mini E, Van Zantwijk CH, Veerman AJP, Peters GJ, Jansen G: Ex vivo activity of methotrexate versus novel antifolate inhibitors of dihydrofolate reductase and thymidylate synthase against childhood leukemia cells. Clin Cancer Res 4:2399, 1998
29. Kamen BA, Eibl B, Cashmore AR, Bertino JR: Uptake and efficiency of trimetrexate (TMQ,2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate resistant leukemia cells in vitro. Biochem Pharmacol 33:1697, 1984
30. Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT: Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331 - a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res 3:911, 1997
31. Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, Smith GK, Waters K, Wilson HR: Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 53:810, 1993
32. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR, Hughes LR: ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical studies. Cancer Res 51:5579, 1991
33. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 57: 1116, 1997
34. Kaspers GJL, Veerman AJP, Pieters R, Broekema GJ, Huismans DR, Kazemier KM, Loonen AH, Rottier MMA, Van Zantwijk CH, Hählen K, Van Wering ER: Mononuclear cells contaminating acute lymphoblastic leukaemic samples tested for cellular drug resistance using the methyl-thiazol-tetrazolium assay. Br J Cancer 70:1047, 1994
35. Lin JT, Bertino JR: Trimetrexate: A second generation folate antagonist in clinical trial. J Clin Oncol 5:2032, 1987
36. Rodenhuis S, McGuire JJ, Narayanan R, Bertino JR: Development of an assay system for the detection and classification of methotrexate resistance in fresh human leukemic cells. Cancer Res 46:6513, 1986
37. Peters GJ, Laurensse EJ, Leyva A, Lankelma J, Pinedo HM: Sensitivity of human, murine and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 46:20, 1986
38. Willey JC, Crawford EL, Jackson CM, Weaver DA, Hoban JC, Khuder SA, DeMuth JP: Expression measurement of many genes simultaneously by quantitative RT-PCR using standardized mixtures of competitive templates. Am J Resp Cell Mol Biol 19:6, 1998
39. Braakhuis BJM, Jansen G, Noordhuis P, Kegel A, Peters GJ: Importance of pharmacodynamics in the in vitro antiproliferative activity of the antifolates methotrexate and 10-ethyl-10-deazaaminopterin against human head and neck squamous cell carcinoma. Biochem Pharmacol 46:2155, 1993
40. McGloskey DE, McGuire JJ, Russell CA, Rowan BG, Bertino JR, Pizzorno G, Mini E: Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 266:6181, 1991
41. Westerhof GR, Kathmann I, Schornagel JH, Jackman AL, Peters GJ, Boyle FT, Pinedo HM, Jansen G: Carrier-and receptor-mediated transport of folate antagonists targetting folate dependent enzymes: Correlates of molecular structure and biological activity. Mol Pharmacol 48:459, 1995
42. Rodenhuis S, McGuire JJ, Sawicki WL, Bertino JR: Effects of methotrexate and of the "nonclassical" folate antagonist trimetrexate on human leukemia cells. Leukemia 1:116, 1987
43. McGuire JJ, Heitzman KJ, Haile WH, Russell CA, McCloskey DE, Piper JR: Cross-resistance studies of folylpolyglutamate synthase-deficiency, methotrexate-resistant CCRF-CEM human leukemia sublines. Leukemia 7:1996, 1993
44. Longo GS, Gorlick R, Tong WP, Lin S, Steinherz P, Bertino JR: Gamma-glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 9:259, 1997
45. Hum M, Holcenberg JS, Tkaczewski I, Weaver JW, Wilson J, Kamen B: High-dose trimetrexate and minimal-dose leucovorin: A case for selective protection? Clin Cancer Res 4:2981, 1998
46. Widemann BC, Balis FM, Reaman GH, Sato J, O'Brian M, Krailo M, Adamson PC: Pediatric phase I trial and phamacokinetic (PK) study of Raltitrexed (ZD 1694, Tomudex). Proc Am Soc Clin Oncol 18:563a, 1999 (abstr)
47. Rots MG, Noordhuis P, Willey JC, Van Zantwijk CH, DeMuth JP, Veerman AJP, Pieters R, Peters GJ, Jansen G: Expression of mRNA encoding for the reduced folate carrier and folate metabolizing enzymes in childhood leukemia cells as measured with a competitive template RT-PCR method. Ann Oncol 9:162, 1998 (abstr)
48. Smith A, Hum M, Winick N, Kamen BA: A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2:69, 1996
49. Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 314:471, 1986
50. Burris HA, Kisor DF, Smetzer LA, Eckardt JR, Rodriguez GI, Rinaldi DA, Lampkin TA, Bigley JW, Von Hoff DD: A phase I pharmacokinetic (pk) study of the thymidylate synthase inhibitor 1843U89 during a daily × 5 bolus administration schedule. Proc Am Soc Clin Oncol 15:477, 1996 (abstr)
51. Rinaldi DA: Overview of phase 1 trials of multitargeted antifolate (MTA, LY231514). Semin Oncol 26:82, 1999